Vergelijking

Pemvidutide vs. Semaglutid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

910463-68-2

Molecuulmassa

geen gegevens

4113.6 g/mol

Halfwaardetijd

geen gegevens

165 h

Sequentie

geen gegevens

modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linker

Werkingsmechanisme

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Bewijsbasis

Hoogste bewijs

Humane studie

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Pemvidutide	Semaglutid
Zwitserland	—	Op recept
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Pemvidutide

Volledige vermelding →

Semaglutid

Volledige vermelding →

Frequently asked questions

What is the difference between Pemvidutide and Semaglutid?: Pemvidutide is classified as "Metabool", while Semaglutid is classified as "Metabool". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pemvidutide or Semaglutid?: The highest available evidence level is "Humane studie" for Pemvidutide and "Humane RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pemvidutide and Semaglutid in Germany and the United States?: Duitsland: Pemvidutide — Niet goedgekeurd, Semaglutid — Op recept. Verenigde Staten: Pemvidutide — Niet goedgekeurd, Semaglutid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Pemvidutide

Semaglutid

Zwitserland

—

Op recept

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Pemvidutide and Semaglutid?

Pemvidutide is classified as "Metabool", while Semaglutid is classified as "Metabool". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pemvidutide or Semaglutid?

The highest available evidence level is "Humane studie" for Pemvidutide and "Humane RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pemvidutide and Semaglutid in Germany and the United States?

Duitsland: Pemvidutide — Niet goedgekeurd, Semaglutid — Op recept. Verenigde Staten: Pemvidutide — Niet goedgekeurd, Semaglutid — Op recept. These are factual summaries with source and review date on the individual pages.